EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study

In this retrospective pilot study, the feasibility of the epithelial cell adhesion molecule (EpCAM) as an imaging target for lymph node (LN) metastatic disease of urothelial cell carcinoma (UCC) of the bladder was investigated. LN metastases and LNs without metastases of patients who underwent pelvic lymph node dissection because of muscle invasive bladder cancer (MIBC) were used. Primary tumors of the same patients were used from cystectomy specimen, transurethral resections, and biopsies. A pathologist, blinded to clinical data, scored EpCAM immunoreactivity. This method determines a total immunostaining score, which is the product of a proportion score and an intensity score. EpCAM expression was observed in 19/20 (95%) LNs with UCC metastases and in 11/12 (92%) of the primary tumors. EpCAM expression was absent in 14/14 (100%) LNs without metastases. Median EpCAM expression (TIS) in LN metastases was 5 (IQR 2.0–8.0) and in the primary tumors 6 (IQR 2.3–11.0). Based on the absence of staining in LNs without metastases, EpCAM show high tumor distinctiveness. EpCAM seems to be a feasible imaging target in LN metastases of UCC of the bladder. Pre- and perioperative visualization of these metastases will improve disease staging and improve the complete resection of LN metastases in MIBC.

[1]  S. Rosati,et al.  EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. , 2014, International journal of molecular sciences.

[2]  T. Katoh,et al.  A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM , 2015, Journal of Molecular Evolution.

[3]  W. Mackillop,et al.  Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study. , 2015, Urologic oncology.

[4]  D. Rubello,et al.  11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard , 2015, Clinical nuclear medicine.

[5]  M. Wirth,et al.  Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy. , 2014, European urology.

[6]  J. Witjes,et al.  The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. , 2014, European urology.

[7]  D. Rubello,et al.  Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings , 2014, Clinical nuclear medicine.

[8]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[9]  M. Zeegers,et al.  Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential , 2013, British Journal of Cancer.

[10]  W. Duan,et al.  Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. , 2013, The international journal of biochemistry & cell biology.

[11]  S. Horenblas,et al.  Impact of 18F‐fluorodeoxyglucose (FDG)‐positron‐emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle , 2013, BJU international.

[12]  V. Goh,et al.  Fluorodeoxyglucose positron‐emission tomography (FDG PET)/computed tomography (CT) in bladder cancer , 2013, BJU international.

[13]  C. Antke,et al.  Is Minimal Residual Lymph Node Disease in Papillary Thyroid Cancer of Prognostic Impact? An Analysis of The Epithelial Cell Adhesion Molecule EpCAM in Lymph Nodes of 40 pN0 Patients , 2013, Pathology & Oncology Research.

[14]  Lucia M. A. Crane,et al.  Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. , 2011, Translational oncology.

[15]  P. Went,et al.  EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.

[16]  J. Ludlow,et al.  Increased Urothelial Cell Detection in the Primary Bladder Smooth Muscle Cell Cultures with Dual MACS/qRT-PCR Approach , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  J. Cizeau,et al.  A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients , 2010, Drug design, development and therapy.

[18]  O. Akin,et al.  Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Schaefer,et al.  EpCAM overexpression is associated with high-grade urothelial carcinoma in the renal pelvis. , 2008, Anticancer research.

[20]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[21]  G. Schäfer,et al.  Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival , 2004, Clinical Cancer Research.

[22]  Gregor Mikuz,et al.  Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.

[23]  J. Izbicki,et al.  Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Izbicki,et al.  Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Stein,et al.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.

[26]  P. Möller,et al.  Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.